Pediatric, adolescent, and young adult osteosarcoma patients have also not benefited from the medical breakthroughs in immunotherapy seen in patients with melanoma and lung cancer, despite evidence of the expression of immune checkpoint receptors such as PD-L1 on osteosarcoma cells and patient tumor specimens. This evidence concerns the gene CD274 and osteosarcoma.